ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Feb 23, 2018
In the News: General Mills, Realty Income, Energy Transfer
General Mills makes a big deal, Realty Income delivers, while Energy Transfer tries to battle back to even.
Feb 22, 2018
Johnson & Johnson in Transition Mode
Image Source: Johnson & Johnson. Shares of Johnson & Johnson have performed well since being added to both the simulated Best Ideas Newsletter portfolio and simulated Dividend Growth Newsletter portfolio. We continue to be impressed with the depth of the clinical pipeline as Johnson & Johnson has an appealing mixture of mature and early-stage products that power the portfolio. Let’s examine the three main franchises of the portfolio to gain a better understanding of the depth of Johnson & Johnson’s Pharmaceutical division.
Feb 21, 2018
Market Valuations Not “Insane” But Certainly Not Cheap Either
The stock market is not insanely overpriced, but it is certainly not cheap either. We’re watching the technicals and moves in the 10-year Treasury closely for signs of where the market may go next. We discuss Walmart’s recent disappointment and add another to the list of companies that the Dividend Cushion ratio effectively highlighted the heightened income risk profile of, prior to the dividend cut. Chipotle is on the move!
Feb 20, 2018
The Future for Independent Advisors and Planners Is…Stock Selection? What?
Image Source: 401K Calculator. "The annual fee of 0.04% to invest in an index ETF, for example, on a portfolio of $250,000 might run about $100/year. Over 25 years, assuming no compounding, that’s $2,500. Setting up a diversified portfolio of 40-50 or so blue-chip, moaty, dividend-paying stocks might cost $200-$300 in total over 25 years, assuming little-to-no turnover, set up through a discount broker. Spread out over dozens of clients, you’re talking real savings for clients."
Feb 18, 2018
A Key Inflection Point for Gilead Sciences
Image Source: Gilead. We have closely followed events at Gilead Sciences for signs of an inflection point as we have long felt the market is myopically focused on the Hepatitis C franchise instead of cash flows. Our decision to add the idea to the simulated Dividend Growth Newsletter portfolio and simulated Best Ideas Newsletter portfolio has played out very well as the share price remains locked in an uptrend. We are updating our thesis following the recent conference call.
Feb 15, 2018
Cisco Rallies Big Time!
Image shown: Performance of the S&P 500 (SPY) since August 2017. As US equities continue their newly-found volatility, let’s take a look at some recent earnings reports and other developments around the markets. Cisco, the workhorse of both simulated newsletter portfolios, put up a fantastic report and upped its dividend. Berkshire continues to love Apple, and we maintain the view that the 10-year Treasury rate may be the greatest determinant of how well stocks perform in the coming decades. Airlines, garbage stocks, the “gas tax,” and more.
Feb 12, 2018
Stocks Stage Comeback, US Government Budget Released
Image shown: The performance of the Dow Jones Industrial Average since September 2017.The market continues to lick its wounds following the sell-off. We’re watching interest rates and technicals for signs where the market may go next.
Feb 9, 2018
Systemic Risk
Image Source: Maximo Santana. We believe the next crisis will not be a banking crisis, but one of a breakdown in market structure.
Feb 8, 2018
Rising Risk Free Rates Threatening Market, Removing CVS and Hanesbrands
The most important variable to keep your eye on, the 10-year Treasury, is rising, and the long-term implications on equity values could be considerable. We don’t think the moves thus far have been too disruptive, but continued concerns over US tax receipts and infrastructure/defense spending could send sovereign yields roaring higher. As fourth-quarter earnings season marches on, let’s take a look at some meaningful recent quarterly reports. We’re also shedding two companies from the simulated newsletter portfolios.
Feb 8, 2018
The Turnaround at Novartis Has Begun
Image Source: Novartis. We believe Novartis is poised to accelerate from the patent cliff caused by the loss of protection of Gleevec, its former top-selling product. The company has a stellar dividend growth history, and the market is anticipating a turnaround once it anniversaries the patent cliff.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.